Scarica l'app Stockscreener
1.12
5.88%
-0.07
Dopo l'orario di chiusura:
1.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ORGS Giù?
Forum
Previsione
Frazionamento azionario
Orgenesis Inc Borsa (ORGS) Ultime notizie
Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Orgenesis (NASDAQ:ORGS) Stock Price Down 6.6% – Time to Sell? - Defense World
Implementation of a Quality Management System for decentralized manufacturing of cell and gene therapy products -technical and regulatory considerations_ von der Leyen et al. -1 -Implementation of a Quality Management System for decentralized manufact - Frontiers
Orgenesis (NASDAQ:ORGS) Stock Price Down 3.6% – What’s Next? - Defense World
GLP-1 Receptor Agonist Market Exclusive Report with Detailed - openPR.com
Genital Warts Treatment Market Deep Research Report Highlights Key PlayersMerck & Co., Inc., Bausch Health - openPR.com
Orgenesis (NASDAQ:ORGS) Shares Down 5.5% – Time to Sell? - Defense World
GLP-1 Receptor Agonist Market Rising Demand and Growth Forecast - openPR.com
Regenerative Therapies Market in 2025-2032 Detailed Study - openPR.com
Orgenesis Delays Filing of Quarterly Report - TipRanks
Orgenesis Announces Stock Repurchase Plan Of Up To $10 Million - Reuters
GLP-1 Receptor Agonist Market Projected To Witness Substantial GRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition Corp.; Pearl Hol - The Manila Times
Nasdaq Announces Delisting of Multiple Companies' Securities Including Alpine 4 Holdings, Inc. and Orgenesis Inc. - Nasdaq
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition... - The Globe and Mail
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition Corp.; Pea - ADVFN
Press Release Distribution & PR Platform - ACCESS Newswire
GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com
ORGENESIS Earnings Preview: Recent $ORGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Orgenesis (NASDAQ:ORGS) Stock Price Up 3.1% – Here’s What Happened - Defense World
How can multimodal and modular cleanrooms satisfy all requirements? - European Pharmaceutical Manufacturer
Point-of-Care Cell and Gene Therapy Manufacturing Market Report 2025-2035Closed-System Bioreactors and AI Bioprocessing Set to Shape PoC Manufacturing by 2035ResearchAndMarkets.com - Bluefield Daily Telegraph
Orgenesis Delays 10-K Filing Amid Financial Challenges - TipRanks
Key Trend Shaping the Common Warts Market in 2025: Enhancing Treatment Efficacy Through Clinical Trials - WhaTech
ORGENESIS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Cell therapy weekly: US$286 million acquisition expands CAR-T manufacturing and commercialization - RegMedNet
Genital Warts Market Growth: Projected to Reach $2.57 Billion by 2029 with an Impressive 5.4% CAGR - WhaTech
Top Companies Developing Cell Therapy Treatments For Diabetes in 2025 - BioInformant
Can This New Spinal Cord Treatment Technology Revolutionize a $7.5B Medical Market? - StockTitan
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
Orgenesis Featured in Special Report on Curing Diabetes - ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 201829/04/2019 - ACCESS Newswire
Stromal Vascular Fraction Market Set to Grow Significantly, - GlobeNewswire
Stem Cell Therapy Market to Grow from $5.8 Billion in 2022 to $19.1 - openPR
Orgenesis Inc. Secures $5 Million Equity Investment, Moves Trading to OTCQXOrgenesis Inc. (NASDAQ: ORGS) recently entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, a Nevada limited liability company. As per the agre - Defense World
Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC) - Defense World
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - StockTitan
Regenerative Xenograft Market 2025-2032: Revenue Growth, Business Opportunities, Trends and Forecast - WICZ
Orgenesis (NASDAQ:ORGS) Stock Price Down 13.1% – What’s Next? - Defense World
UBS Group Lowers YETI (NYSE:YETI) Price Target to $43.00 - Defense World
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Orgenesis announces director resignation - Investing.com
Critical Contrast: Orgenesis (NASDAQ:ORGS) vs. BridgeBio Pharma (NASDAQ:BBIO) - Defense World
Viral Vector Production (Research-use) Market Size to Hit USD 7.62 Bn by 2034 - BioSpace
Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Opportunity Analysis and Forecast, 2024-2030 - openPR.com
Orgenesis Inc. sees insider transactions totaling $16,259 in sales By Investing.com - Investing.com India
7 Companies Owned by Pfizer - Investopedia
3D Bioprinting for Tissue and Organ Regeneration Market to Reach $424.3 Million by 2030 As Revealed In New ... - WhaTech
Orgenesis Inc. Reports Q3 2024 Financial Results - TipRanks
Orgenesis Provides Third Quarter 2024 Business Update - The Manila Times
Orgenesis Inc. announces director resignation, remains advisor - Investing.com
Orgenesis Commences Trading on OTCQX® Best Market - Yahoo Finance
Don’t rule out Hyundai selling Kia or Genesis to Toyota - Auto Express
United States shares higher at close of trade; Dow Jones Industrial Average up 0.09% - Investing.com India
3.40%
2.49%
Capitalizzazione:
|
Volume (24 ore):